ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2019
ATP-citrate lyase is an epigenetic regulator to promote obesity-related kidney injury.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Emerging roles of ATP citrate lyase in kidney diseases: from pathogenic driver to therapeutic target.Renal failure · 2026Review
- Lipids in kidney diseases: from systemic imbalance to intrarenal alterations of cellular lipid metabolism in rare and common kidney diseases.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Metabolic reprogramming in cardiac fibrosis: mechanisms, crosstalk, and therapeutic interventions.Frontiers in physiology · 2026Review
- The role of lipid profile in the relationship between skipping breakfast and hyperuricemia: a moderated mediation model.BMC public health · 2025Article
- Obesity-Related Kidney Disease in Bariatric Surgery Candidates.Obesity surgery · 2025Article
- Inflammatory and lipotoxicity mechanisms in obesity related CKD.Frontiers in nephrology · 2025Review
- The Lipid-Oxidative Stress Axis: Novel Therapeutic Targets for Podocytopathy.Journal of inflammation research · 2025Review
- Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease.Cell metabolism · 2024Article
- Article
- Effect of alpha-lipoic acid and caffeine-loaded chitosan nanoparticles on obesity and its complications in liver and kidney in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2023Article
- Role of sodium dependent SLC13 transporter inhibitors in various metabolic disorders.Molecular and cellular biochemistry · 2023Review
- Modeling SILAC Data to Assess Protein Turnover in a Cellular Model of Diabetic Nephropathy.International journal of molecular sciences · 2023Article
- ACLY and CKD: A Mendelian Randomization Analysis.Kidney international reports · 2022Article
- Obesity-related glomerulopathy: Current approaches and future perspectives.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022Review
- ATP-citrate lyase inhibitor improves ectopic lipid accumulation in the kidney in a db/db mouse model.Frontiers in endocrinology · 2022Article
- Identification of potential target genes of breast cancer in response to Chidamide treatment.Frontiers in molecular biosciences · 2022Article
- Involvement of Tricarboxylic Acid Cycle Metabolites in Kidney Diseases.Biomolecules · 2021Review
- Unraveling the epigenetic landscape of glomerular cells in kidney disease.Journal of molecular medicine (Berlin, Germany) · 2021Review
- High-fat diet promotes renal injury by inducing oxidative stress and mitochondrial dysfunction.Cell death & disease · 2020Article
- TheCells · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Obesity is a leading cause of chronic kidney disease (CKD), but how obesity promotes renal injury remains poorly understood. Here we showed that ATP-citrate lyase (ACL), an enzyme converting citrate to acetyl-CoA, is highly induced in the kidney of overweight or obese patients with CKD and ob/ob BTBR mice. ACL induction is associated with increased ectopic lipid accumulation (ELA), glomerulosclerosis, and albuminuria. Acetyl-CoA is the substrate for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.